Literature DB >> 6263447

Intraarterial cis-platinum for patients with inoperable skeletal tumors.

G M Mavligit, R Benjamin, Y Z Patt, N Jaffe, V Chuang, S Wallace, J Murray, A Ayala, S Johnston, E M Hersh, D B Calvo.   

Abstract

Twenty-three patients with inoperable skeletal tumors were treated with intraarterial cis-platinum prior to attempted surgery. The antitumor effect of intraarterial cis-platinum was monitored clinically by radiologic imaging techniques, and whenever possible, evaluated histopathologically by examinatin of surgical or biopsy tumor specimens. Objective responses were noted in 12 patients (52%) and included 2 complete, 7 partial and 3 less-than-partial remissions lasting from 14 to 70 weeks. Limb-saving surgery or hemipelvectomy became subsequently feasible in four and one patients respectively. Preoperative intraarterial cis-platinum is a safe procedure which might be used effectively in combination with other, more conventioal postoperative adjuvant chemotherapy against skeletal tumors.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6263447     DOI: 10.1002/1097-0142(19810701)48:1<1::aid-cncr2820480102>3.0.co;2-r

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

Review 1.  Therapy of bladder cancer.

Authors:  K H Bichler; S Halim
Journal:  Int Urol Nephrol       Date:  1987       Impact factor: 2.370

2.  Case report 669: Osteonecrosis of bone associated with intraarterial therapy using cisplatin.

Authors:  P Wuisman; R Erlemann; A Roessner; A Bosse; C Kusniez-Glaz
Journal:  Skeletal Radiol       Date:  1991       Impact factor: 2.199

3.  Intraarterial chemotherapy for extremity osteosarcoma and MFH in adults.

Authors:  Ronald R Hugate; Ross M Wilkins; Cynthia M Kelly; Walt Madsen; Ioana Hinshaw; Anne B Camozzi
Journal:  Clin Orthop Relat Res       Date:  2008-04-25       Impact factor: 4.176

Review 4.  Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective.

Authors:  Robert S Benjamin
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.